Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2618 combinations in relapsed extensive-stage small cell lung cancer
CTR20221911Phase 2Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of TQB2618, benmelstobart, penpulimab in small cell lung cancer (SCLC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Aug 2022; status: terminated.
02
Drugs
TQB2618benmelstobartpenpulimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20221911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221911.